MTAR Technologies has rescheduled its in-person group meeting with analysts and institutional investors, followed by a plant visit, on August 21, 2026. The company revised the timing of the event to start at 10:00 am and end at 2:00 pm. This update supersedes the earlier schedule which had set the start time at 7:30 am.

The company issued the intimation on August 18, 2026, pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This disclosure aligns with Part A of Schedule III of the same regulations, ensuring transparency for stakeholders regarding investor engagement activities.

Revised event details

The meeting aims to provide investors with direct access to management and operational facilities. Key logistical details are outlined below:

Priyanka Agarwal, Director and Company Secretary at MTAR Technologies, signed the disclosure.

MTAR Technologies delivered its strongest quarterly performance in Q1 FY27, reporting a record revenue from operations of ₹360.7 crore, up 130.4% year-on-year from ₹156.6 crore in Q1 FY26. The surge was underpinned by robust execution across its key business verticals—civil nuclear power, clean energy, and aerospace & defense—alongside significant improvements in working capital efficiency. This performance places the company on track to exceed its earlier guidance of 80% revenue growth for the current fiscal year.

The financial results reflect a sharp acceleration in profitability metrics. EBITDA rose 199.7% to ₹85.1 crore, while profit before tax increased 355% to ₹67.4 crore. Consequently, profit after tax (PAT) surged 364.5% to ₹50.2 crore, compared to ₹10.8 crore in the corresponding period last year. Management attributed the growth to higher volume production in previously qualified products and strong demand in emerging segments like data center infrastructure solutions.

Financial Performance Highlights

Operational Updates and Order Book

The company’s order book stood at ₹5,143 crore at the end of the quarter, receiving an additional ₹800 crore in orders during the reporting period. In the civil nuclear segment, MTAR secured its highest-ever order inflows for the Kaiga 5 & 6 reactors and anticipates further orders from reactor refurbishment projects. The fast breeder reactor program recently achieved criticality, with MTAR having supplied a majority of the critical assemblies. Looking ahead, the proposed development of four nuclear reactors at Mahi Banswara presents a significant opportunity, with management estimating potential orders exceeding those from Kaiga 5 & 6.

In the clean energy vertical, record order inflows strengthened the pipeline. Capacity augmentation for fuel cells is proceeding in three phases: Phase 1 is commissioned, Phase 2 is targeted for September-October 2026, and Phase 3—a multifold expansion—is scheduled for completion by March 2027. Additionally, MTAR has entered the data center infrastructure solutions segment with an initial order of ₹45 crore, part of a larger potential requirement eight times this size, primarily for export markets.

What the Numbers Show

A critical analytical observation from the filing is the dramatic improvement in working capital management, which has directly fueled cash flow generation. Working capital days dropped significantly to 59 days in Q1 FY27, down from 172 days in FY26 and well below the annual guidance of 150–175 days. This efficiency gain was driven by better commercial terms negotiated with customers and rigorous daily monitoring of receivables and inventory. As a result, cash flow from operations reached ₹247.69 crore, up from ₹191.66 crore in Q1 FY26. Despite this, gross margins slightly contracted to 45.61% from 47.65% in Q1 FY26 due to revenue mix changes, though EBITDA margins improved to 23.6% through operating leverage.

Capital Allocation and Outlook

MTAR plans to incur approximately ₹500 crore in capital expenditure over the next two years to support capacity expansions across all verticals. Of this, 70% is allocated to clean energy and 30% to other segments. For Q1 FY27, the company incurred around ₹35 crore in capex. The balance sheet remains strong, with net debt effectively negligible after adjusting investments of ₹379 crore against total debt of ₹423.6 crore as of June 30, 2026. Management reiterated confidence in achieving an EBITDA margin of 24% ± 100 basis points for FY27 and expects ROCE to reach 23% in the coming year.